suPAR as a biomarker of support in different clinical settings

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-04-11 DOI:10.1016/j.cca.2025.120303

Fabio Belvederi , Simone Leggeri , Andrea Urbani , Silvia Baroni

引用次数: 0

Abstract

The urokinase-type plasminogen activator receptor (uPAR) system, which includes protease, receptor and inhibitors, is essential for key cellular functions like immune activation, cell migration, and tissue remodeling. Soluble uPAR (suPAR), released into circulation, serves as a valuable biomarker for systemic inflammation and immune activation. Elevated suPAR levels are associated with disease severity in conditions such as infections, sepsis, cardiovascular diseases, renal injury, cancer, and autoimmune diseases providing prognostic value especially in acute settings.

Recent advancements in diagnostic methods, have enhanced the accuracy of suPAR measurement in serum and plasma. New rapid tests, such as suPARnostic Quick Triage, as well as turbidimetric assays, further expand its clinical applicability.

In this review, we discuss the suPAR biomarker, focusing on its biochemical structure, biological functions, measurement methods and areas of clinical interest in different fields of medicine.

查看原文本刊更多论文

suPAR在不同临床环境中作为支持的生物标志物

尿激酶型纤溶酶原激活物受体（uPAR）系统包括蛋白酶、受体和抑制剂，对免疫激活、细胞迁移和组织重塑等关键细胞功能至关重要。可溶性uPAR （suPAR）释放到循环中，作为系统性炎症和免疫激活的有价值的生物标志物。suPAR水平升高与感染、败血症、心血管疾病、肾损伤、癌症和自身免疫性疾病等疾病的严重程度有关，尤其在急性情况下具有预后价值。诊断方法的最新进展提高了血清和血浆中suPAR测量的准确性。新的快速检测，如超诊断快速分类，以及浊度测定，进一步扩大了其临床适用性。本文就suPAR生物标志物在不同医学领域的生物化学结构、生物学功能、测量方法和临床研究热点等方面进行综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.